Our Products
Glaucoma is the second leading cause of blindness, affecting ~400,000 Canadians, and ~100 million
people worldwide.
The economic cost of vision loss in Canada is estimated at over $16 billion annually, including
direct health costs, productivity losses and financial aid for patients.
This disease is characterized by
degeneration of Retinal Ganglion Cells (RGCs) via programmed cell death.
RGCs carry visual signals from the
retina to the brain, and hence, progressive RGC loss leads to blindness.
We have discovered peptide therapeutics that prevent RGC degeneration, and preserve visual function.